자가면역 질환 예방 및 치료를 위한 TNFR2를 기반으로 하는 이중 항체
    21.
    发明公开
    자가면역 질환 예방 및 치료를 위한 TNFR2를 기반으로 하는 이중 항체 有权
    基于TNFR2的预防和治疗自身免疫性疾病的双重抗体

    公开(公告)号:KR1020130126550A

    公开(公告)日:2013-11-20

    申请号:KR1020130053373

    申请日:2013-05-10

    Abstract: The present invention relates to a bispecific antibody which is specific to IL-6R and TNF-alpha and a pharmaceutical composition containing the same for preventing and treating autoimmune diseases. The bispecific antibody of the present invention contains (a) an interleukin-6 receptor (IL-6R)-specific monoclonal antibody; and tumor necrosis factor receptor type 2 (TNFR2) proteins which is linked at C-terminal of a constant region of the monoclonal antibody or a fragment containing extracellular region of TNFR2 and is specific to IL-6R and TNF-alpha.

    Abstract translation: 本发明涉及对IL-6R和TNF-α特异性的双特异性抗体以及含有该双特异性抗体的预防和治疗自身免疫疾病的药物组合物。 本发明的双特异性抗体含有(a)白细胞介素-6受体(IL-6R)特异性单克隆抗体; 和肿瘤坏死因子受体2型(TNFR2)蛋白,其在单克隆抗体的恒定区的C末端或含有TNFR2的胞外区的片段连接并且对IL-6R和TNF-α是特异性的。

    항 IL-6R 및 TNFR2을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 자가 면역 질환 치료용 약학 조성물
    22.
    发明公开
    항 IL-6R 및 TNFR2을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 자가 면역 질환 치료용 약학 조성물 有权
    一种用于预防和治疗包含表达包含抗IL-6R和TNFR2的双向蛋白的微量载体的自身免疫性疾病的药物组合物

    公开(公告)号:KR1020130126543A

    公开(公告)日:2013-11-20

    申请号:KR1020130053249

    申请日:2013-05-10

    CPC classification number: A61K48/00 C12N15/63 Y10S424/81 Y10S514/825

    Abstract: The present invention relates to a pharmaceutical composition containing a vector for treating immune diseases, which expresses bispecific proteins containing anti-IL-6R and TNFR2. The pharmaceutical composition of the present invention relates to a pharmaceutical composition for preventing and treating autoimmune diseases, containing (a) a gene expression cassette; (b) a site-specific recombinant region located at the outside of the gene expression cassette; and (c) a non-viral vector which does not contain a replication origin and a selection marker gene.

    Abstract translation: 本发明涉及含有用于治疗免疫疾病的载体的药物组合物,其表达含有抗IL-6R和TNFR2的双特异性蛋白质。 本发明的药物组合物涉及含有(a)基因表达盒的自身免疫疾病的预防和治疗用药物组合物, (b)位于基因表达盒外侧的位点特异性重组区; 和(c)不含复制起点和选择标记基因的非病毒载体。

    류마티스 관절염 치료용 조성물
    24.
    发明公开
    류마티스 관절염 치료용 조성물 有权
    用于治疗恶性肿瘤的组合物

    公开(公告)号:KR1020130063627A

    公开(公告)日:2013-06-17

    申请号:KR1020110130073

    申请日:2011-12-07

    CPC classification number: A61K35/08 A23L33/10 A61K33/00 Y10S514/825

    Abstract: PURPOSE: A composition containing marine minerals and essential inorganic salts for treating rheumatoid arthritis is provided to treat and alleviate rheumatoid arthritis. CONSTITUTION: A composition for treating rheumatoid arthritis contains marine mineral water which is collected underground at a depth of 1100 m at a hot spring of the coastal terrace 92-1, Geumjin-ri, Okgye-myeon, Gangneung-si, Ganwon-do in Korea. The mineral water is a concentrate water containing 200-230 mg/L of potassium, 7000-9500 mg/L of sodium, 1400-1700 mg/L of calcium, 900-1100 mg/L of magnesium, 3-9 mg/L of zinc, 25-35 mg/L of strontium, 200-500 Mg/L of selenium, 65-75 Mg/L of vanadium, 0.5-1.5 Mg/L of germanium, 10-40 Mg/L of manganese, 1-3 Mg/L of cobalt, 600-950 Mg/L of titanium, 3-9 Mg/L of copper, 0.02-0.09 mg/L of lithium, 16000-19500 mg/L of chlorine ion, 1.5-3.0 mg/L of fluorine ion, 40-56 mg/L of bromide ion, 3000-4500 mg/L of sulfate ion, 0.8-1.2 mg/L of boron, and 0.5-1.5 mg/L of silicon dioxide. The composition contains 0.5-50 wt% of the concentrate.

    Abstract translation: 目的:提供含有海洋矿物质和治疗类风湿关节炎的必需无机盐的组合物,用于治疗和缓解类风湿性关节炎。 构成:用于治疗类风湿关节炎的组合物含有海水矿物质水,其在1100m深度的地下采集在甘肃省江陵市O ye,,jin仁海滨露台92-1的温泉处 韩国。 矿泉水是含有200-230mg / L的钾,7000-9500mg / L的钠,1400-1700mg / L的钙,900-1100mg / L的镁,3-9mg / L的浓缩水 的锌,25-35mg / L的锶,200-500Mg / L的硒,65-75Mg / L的钒,0.5-1.5Mg / L的锗,10-40Mg / L的锰,1- 3 Mg / L钴,600-950 Mg / L钛,3-9 Mg / L铜,0.02-0.09 mg / L锂,16000-19500 mg / L氯离子,1.5-3.0 mg / L 的氟离子,40-56mg / L溴离子,3000-4500mg / L硫酸根离子,0.8-1.2mg / L硼和0.5-1.5mg / L二氧化硅。 组合物含有0.5-50重量%的浓缩物。

    항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료
    30.
    发明公开
    항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료 有权
    使用设计用于表达TNFR2的微型矢量进行自发性疾病的治疗

    公开(公告)号:KR1020130126549A

    公开(公告)日:2013-11-20

    申请号:KR1020130053356

    申请日:2013-05-10

    Abstract: The present invention relates to a pharmaceutical composition containing a minicircle vector which expresses tumor necrosis factor receptor type 2 (TNFR2) for treating autoimmune diseases. The pharmaceutical composition of the present invention contains: (a) a gene expression cassette containing a promoter, a gene encoding TNFR2 proteins or a fragment containing extracellular region of TNFR2, and a terminator; b) a site-specific recombinant region located at the outside of the gene expression cassette; and a non-viral vector which does not contain a replication origin and a selection marker gene as active ingredients.

    Abstract translation: 本发明涉及含有表达用于治疗自身免疫性疾病的2型肿瘤坏死因子受体(TNFR2)的小环载体的药物组合物。 本发明的药物组合物含有:(a)含有启动子,编码TNFR2蛋白的基因或含有TNFR2胞外区的片段的基因表达盒和终止子; b)位于基因表达盒外侧的位点特异性重组区; 和不含复制起点和选择标记基因作为活性成分的非病毒载体。

Patent Agency Ranking